Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Tirzepatide for Sale > Hot sale Peptide Tirzepatide 30mg TR30 2023788-19-2
Hot sale Peptide Tirzepatide 30mg TR30 2023788-19-2 buy - large image1
Hot sale Peptide Tirzepatide 30mg TR30 2023788-19-2 buy - image1
Hot sale Peptide Tirzepatide 30mg TR30 2023788-19-2 buy - image2
Hot sale Peptide Tirzepatide 30mg TR30 2023788-19-2 buy - image3
Hot sale Peptide Tirzepatide 30mg TR30 2023788-19-2 buy - image4
Hot sale Peptide Tirzepatide 30mg TR30 2023788-19-2 buy - image5
Hot sale Peptide Tirzepatide 30mg TR30 2023788-19-2 buy - image6

Hot sale Peptide Tirzepatide 30mg TR30 2023788-19-2

2103 Inquiries

Unit Price:

$86/MT EXW

Get Latest Price
CAS No.:

2023788-19-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

shenzhen

Packaging:

10 vials/box

Price valid (until):

2027-09-01

Company Type:
Trader
Location:
Hongkong, China
Qualification:
Main Products:

Retatrutide

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


      Contact information  


    Name:Iris

    Email:Xb20050416@gmail.com

    WhatsApp:+852 6391 4517


      Product Detail  


      Tirzepatide  is a novel dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, primarily used to treat type 2 diabetes and obesity. By activating GIP and GLP-1 receptors, tirzepatide enhances insulin secretion, inhibits glucagon release, and delays gastric emptying. This dual mechanism not only effectively lowers blood glucose levels but also reduces appetite via the central nervous system, thereby facilitating weight management.

    Name Tirzepatide
    CAS NO. 2023788-19-2
    Specifications 30mg
    Purity 99%


      Product Photos Shop Hot sale Peptide Tirzepatide 5mg TR5 2023788-19-2-Detailed Image 1 Shop Hot sale Peptide Tirzepatide 5mg TR5 2023788-19-2-Detailed Image 2


    Shop Hot sale Peptide Tirzepatide 5mg TR5 2023788-19-2-Detailed Image 3
    Shop Hot sale Peptide Tirzepatide 5mg TR5 2023788-19-2-Detailed Image 4
    Shop Hot sale Peptide Tirzepatide 5mg TR5 2023788-19-2-Detailed Image 5


      Packing & Delivering  


    We utilize dedicated transport routes, ensuring fast, safe, and efficient delivery.

    Shop Hot sale Peptide Tirzepatide 5mg TR5 2023788-19-2-Detailed Image 6


    ECHEMI Editorial Reference

    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Retatrutide

    Location:

    B27 SHING LEE COMM BLDG 8 WING KUT ST CENTRAL HONG KONG

    Year of Establishment:

    2026

  • Inquiry History
    2103 Inquiries
    Country Product Purchase Quantity Date Posted
    Brazil

    Tirzepatide

    100 G Oct 28, 2026
    Belgium

    Tirzepatide

    10 MG Oct 28, 2026
    United States

    tirzepatide

    100 MG Oct 28, 2026
    United States

    Tirzepatide

    60 MG Oct 28, 2026
    United States

    Tirzepatide

    10 PCS Oct 28, 2026
    United States

    tirzepatide

    30 MG Oct 27, 2026
    United States

    Tirzepatide

    40 MG Oct 27, 2026
    Philippines

    Tirzepatide

    2 MT Oct 27, 2026
    Philippines

    Tirzepatide

    30 MG Oct 26, 2026
    Slovakia

    Tirzepatide

    1 G Oct 26, 2026
    France

    Tirzepatide

    1 KG Oct 25, 2026
    United States

    Tirzepatide

    2.5 MG Oct 25, 2026
    United Kingdom

    Tirzepatide

    5 MT Oct 25, 2026
    United Kingdom

    Tirzepatide

    6 MT Oct 24, 2026
    Peru

    tirzepatide

    10 MG Oct 21, 2026
    Puerto Rico

    tirzepatide

    40 MG Oct 21, 2026
    United States

    Tirzepatide

    10 MT Oct 21, 2026
    South Africa

    Tirzepatide

    1 MT Oct 20, 2026
    United States

    Tirzepatide

    5 KG Oct 20, 2026
    United States

    tirzepatide

    30 MG Oct 20, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.